Niagen Bioscience Reports Mixed Q1 2026: Revenue Up, EBITDA Down
Event summary
- Q1 2026 revenue rose 3% YoY to $31.5M, with 5% growth excluding divested segment.
- Gross margin improved to 63.5%, but adjusted EBITDA fell to $3.8M from $4.9M YoY.
- Net income increased to $6.3M, boosted by $4.8M gain from divestiture of Analytical Reference Standards segment.
- Launched clinician-directed telehealth platform and expanded cruise ship clinic partnerships.
- Completed divestiture of Analytical Reference Standards segment to LGC Standards.
The big picture
Niagen Bioscience is streamlining operations to focus on core NAD+ science and commercial growth, following the divestiture of its Analytical Reference Standards segment. The company is expanding its reach through telehealth and premium wellness channels, while navigating increased investment in sales and marketing. The mixed Q1 results highlight the tension between growth initiatives and financial discipline in the competitive bioscience sector.
What we're watching
- Execution Risk
- Whether Niagen can sustain revenue growth while increasing sales and marketing investments.
- Market Expansion
- The pace at which new strategic partnerships and telehealth initiatives drive commercial growth.
- Financial Discipline
- How the company balances increased operating expenses with profitability goals.
Related topics